T-cell prolymphocytic leukemia

Medical Oncology

Volumn 23, Issue 1, 2006, Pages 17-22

  Dearden, Claire E ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Alemtuzumab; T PLL

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GEMCITABINE; MITOXANTRONE; ONCOPROTEIN; PENTOSTATIN; PREDNISONE; PROTEIN MTCP 1; PROTEIN TCL 1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CLINICAL TRIAL; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DRUG RESPONSE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPHENOTYPING; INFECTION COMPLICATION; INFUSION RELATED SIDE EFFECT; LEUKEMOGENESIS; LYMPHOCYTOPENIA; PATHOGENESIS; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PROTO ONCOGENE; RECEPTOR GENE; REVIEW; SIDE EFFECT; T CELL LEUKEMIA; T CELL PROLYMPHOCYTIC LEUKEMIA; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, PROLYMPHOCYTIC; LEUKEMIA, T-CELL; MALE; MIDDLE AGED;

EID: 33646873505     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:1:17     Document Type: Review

References (28)

1. Catovsky D, Galetto J, Okos A, Galton DA, Wiltshaw E, Stathopoulos G. Prolymphocytic leukaemia of B and T cell type. Lancet 1973; 2:232-234.
2. Matutes E, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991; 78:3269-3274.
3. Matutes E, Brito-Babapulle V, Yuille M, Catovsky D, Dearden C. Prolymphocytic leukemia of B- and T-cell types. In: Cheson BD (ed.) Chronic lymphoid leukemias. Marcel Dekker, Inc.: New York, Basel, 2001, pp. 525-541.
4. Garand R, et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais d'Hematologie Cellulaire. Br J Haematol 1998; 103: 488-494.
5. Matutes E, Garcia Talavera J, O'Brien M, Catovsky D. The morphological spectrum of T-prolymphocytic leukaemia. Br J Haematol 1986; 64:111-124.
6. Brito-Babapulle V, Maljaie SH, Matutes E, Hedges M, Yuille M, Catovsky D. Relationship of T leukaemias with cerebriform nuclei to T-prolymphocytic leukaemia: a cytogenetic analysis with in situ hybridization. Br J Haematol 1997; 96:724-732.
7. Pawson R, Schulz TF, Matutes E, Catovsky D. The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Leukemia 1997; 11:1305-1311.
8. Ginaldi L, Matutes E, Farahat N, De Martinis M, Morilla R, Catovsky D. Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry. Br J Haematol 1996; 93:921-927.
9. Ginaldi L, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998; 22:185-191.
10. Sugimoto T, et al. T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype. Ann Hematol 2001; 80:749-751.
11. Soulier J, et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 2001; 31:248-254.
12. Croce CM, et al. Gene for alpha-chain of human T-cell receptor: location on chromosome 14 region involved in T-cell neoplasms. Science 1985; 227:1044-1047.
13. Virgilio L, et al. TCL1 is overexpressed in patients affected by adult T-cell leukemias. Cancer Res 1997; 57:5452-5456.
14. Stern MH, et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene 1993; 8: 2475-2483.
15. Madani A, et al. Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. Blood 1996; 87:1923-1927.
16. Yuille MR, et al. TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosomes Cancer 2001; 30:336-341.
17. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000; 6:395-407.
18. Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev 1996; 10:2411-2422.
19. Stilgenbauer S, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 1997; 3:1155-1159.
20. Stoppa-Lyonnet D, et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood 1998; 91:3920-3926.
21. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994; 12: 2588-2593.
22. Delgado J, Bustos JG, Jimenez MC, Quevedo E, Hernandez-Navarro F. Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders? Leuk Lymphoma 2002; 43:2331-2334.
23. Pawson R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997; 15:2667-2672.
24. Dearden CE, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98:1721-1726.
25. Keating MJ, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002; 20: 205-213.
26. Dearden C, et al. Very high response rates in previously untreated T-cell prolymphocytic leukaemia patients receiving alemtuzumab (Campath-1H) therapy. Blood 2003; 102:644a.
27. Hopfinger G, et al. T-PLL-1 Protocol of the German CLL Study Group (GCLLSG) - a prospective phase II trial of fludarabine phosphate, mitoxantrone ans cyclophosphamide (FMC) followed by alemtuzumab consolidation as first line treatment in T-PLL. Blood 2003; 102: abstract 2495.
28. Weidmann E, et al. Combination chemo-immunotherapy using alemtuzumab, fludarabine, cyclophosphamide and doxorubicin (FCD) is an effective first line regimen in peripheral T-cell lymphoma (PTCL). Blood 2004; 104, abstract 2640.